17 February 2021 - First approved treatment for adult and paediatric patients with long-chain fatty acid oxidation disorders in Canada.
Ultragenyx today announced that Health Canada has approved Dojolvi (triheptanoin) as a source of calories and fatty acids for the treatment of adult and paediatric patients with long-chain fatty acid oxidation disorders.
Dojolvi is a highly purified, synthetic, 7 carbon fatty acid triglyceride specifically designed to provide medium-chain, odd-carbon fatty acids as an energy source and metabolite replacement for people with long-chain fatty acid oxidation disorders.